Compare Cronos Group Inc (CRON) vs Nutanix Inc (NTNX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cronos Group Inc vs Nutanix Inc — how do they compare? Cronos Group Inc trades at $3.13 (market cap $1.14B), while Nutanix Inc trades at $63.85 (market cap $17.39B). The key difference: Nutanix Inc is far larger — about 15.3× Cronos Group Inc's market cap, and Cronos Group Inc is trading nearer its 52-week high, Nutanix Inc nearer its low. Which is the better fit depends on your goals.
| CRON | NTNX | |
|---|---|---|
Market Cap | $1.14B | $17.39B |
Sector | Health | Technology |
52-Week High | $3.27 | $81.12 |
52-Week Low | $2.30 | $34.41 |
Enterprise Value | $341.13M | $16.90B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRON trades at $3.00, down 3.23% today, with a bullish technical signal from moving averages. The company showed strong Q2 2026 performance with 58% YoY revenue growth and earnings beat, though recent quarters were mixed. Valuation metrics include P/E of 16.21 and P/S of 6.55, while profitability improved with 45.86% gross margin. Analyst consensus is mixed with 20% buy, 60% hold ratings.
Outlook remains positive due to international expansion and strong product positioning, particularly in Canada and Europe. Key risks include competitive pressures and cash flow volatility from aggressive investing. The stock presents growth potential but requires monitoring of execution and market conditions.
Nutanix (NTNX) trades at $63.74, down 1.12% today, showing strong fundamental momentum with consistent earnings beats and robust revenue growth. The stock maintains a bullish technical outlook with moving averages supporting upward momentum, though RSI levels suggest potential overbought conditions. Recent institutional buying activity and positive analyst sentiment (62.5% buy ratings) reflect confidence in the hybrid multicloud platform's growth trajectory.
Outlook remains positive with Q4 earnings expected to beat consensus, though supply chain constraints pose near-term risks. The company's expanding profit margins and VMware migration opportunities provide upside potential, but elevated valuation metrics (P/E 67.71) require continued execution. Investors should monitor Q2 2026 earnings results due August 26th for confirmation of growth sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cronos Group Inc
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →About Nutanix Inc
Nutanix, Inc. is a global leader in cloud software and hyperconverged infrastructure (HCI) solutions. The company's platform converges computing, virtualization, and storage into a single, seamless software-defined solution, enabling private, hybrid, and multi-cloud environments. Nutanix helps organizations simplify data center operations, manage their applications across various cloud platforms, and reduce IT complexity, positioning it as a key enabler of modern hybrid cloud strategies.
Read more on NTNX →
